Figure 3.

Abundance of C4b-binding protein α chain (C4BPA), clusterin (CLU), and α-1-antitrysin (SERPINA1) in pediatric/adolescent patients with non-relapsed (NR) and relapsed (R) HL (validation phase). Non-relapsed and relapsed patients were divided according to whether or not they had an adequate (AR) or inadequate (IR) response to therapy on early response assessment, as explained in the Materials and Methods. Data are expressed as LFQ values obtained with LC-MS/MS (a–c,g–i), or as band intensities from immunoblotting (d–f). In (a–c,g–i), the crosses indicate the mean value of the parameter tested, and the other symbols (squares, rhombuses, triangles, and circles) indicate individual patients. * Significance for p-value < 0.05. NR, non-relapsed; R, relapsed.